The Combined Dexamethasone/CRH Test (DEX/CRH Test) and Prediction of Acute Treatment Response in Major Depression
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In this study the predictive value of the combined dexamethasone/CRH test (DEX/CRH test) for acute antidepressant response was investigated. METHODOLOGY/PRINCIPAL FINDINGS: In 114 depressed inpatients suffering from unipolar or bipolar depression (sample 1) the DEX/CRH test was performed at admission and shortly before discharge. During their stay in the hospital patients received different antidepressant treatment regimens. At admission, the rate of nonsuppression (basal cortisol levels >75.3 nmol/l) was 24.6% and was not related to the later therapeutic response. Moreover, 45 out of 114 (39.5%) patients showed an enhancement of HPA axis function at discharge in spite of clinical improvement. In a second sample, 40 depressed patients were treated either with reboxetine or mirtazapine for 5 weeks. The DEX/CRH test was performed before, after 1 week, and after 5 weeks of pharmacotherapy. Attenuation of HPA axis activity after 1 week was associated with a more pronounced alleviation of depressive symptoms after 5-week mirtazapine treatment, whereas downregulation of HPA system activity after 5 weeks was related to clinical response to reboxetine. However, early improvement of HPA axis dysregulation was not necessarily followed by a beneficial treatment outcome. CONCLUSIONS/SIGNIFICANCE: Taken together, performance of a single DEX/CRH test does not predict the therapeutic response. The best predictor for response seems to be an early attenuation of HPA axis activity within 1 or 2 weeks. However, early improvement of HPA system dysfunction is not a sufficient condition for a favourable response. Since a substantial part of depressive patients display a persistence of HPA axis hyperactivity at discharge, downregulation of HPA system function is not a necessary condition for acute clinical improvement either. Our data underline the importance of HPA axis dysregulation for treatment outcome in major depression, although restoration of HPA system dysfunction seems to be neither a necessary nor a sufficient determinant for acute treatment response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The combined dexamethasone–corticotropin-releasing hormone (DEX/CRH) test, a measure of HPA axis (dys)regulation, is altered in 24–35% of patients with acute depression (Schüle et al. 2009).”
From Ex vivo glucocorticoid receptor-mediated IL-10 response predicts the course of depression severity (2021) · cites this paper as Schüle et al. 2009
In the citing paper
“non-suppression in the DEX/CRH test at baseline was not related to later therapeutic response in a former study (Schule et al. 2009)”
From Ex vivo glucocorticoid receptor-mediated IL-10 response predicts the course of depression severity (2021) · cites this paper as Schule et al. 2009
In the citing paper
“improved HPA responsiveness within the first 1–3 weeks of treatment predicts improvement of depressive symptoms”
From Ex vivo glucocorticoid receptor-mediated IL-10 response predicts the course of depression severity (2021) · cites this paper as Schüle et al. (2009)
In the citing paper
“studies also have shown clinical remission despite persisting GR dysfunction (Schule et al. 2009)”
From Ex vivo glucocorticoid receptor-mediated IL-10 response predicts the course of depression severity (2021) · cites this paper as Schule et al. 2009
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Carroll, B. J. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780260017001 · Cited by 2,243
The Corticosteroid Receptor Hypothesis of Depression
Holsboer, F. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00159-7 · Cited by 2,181
Nemeroff, C. B., Widerlöv, E., Bissette, G., Walléus, H., Karlsson, I., Eklund, K., Kilts, C. D., Loosen, P. T., & Vale, W. (1984) · Science · doi:10.1126/science.6334362 · Cited by 1,485 · cited 2×
“In depressed patients, elevated cortisol (COR) and adrenocorticotrophic hormone (ACTH) concentrations in the plasma [3–6] or in the cerebrospinal fluid (CSF) [7] have been found.”
BackgroundGlucocorticoid receptors in major depression: relevance to pathophysiology and treatment
Pariante, C. M., & Miller, A. H. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01088-x · Cited by 1,147 · cited 1×
“Moreover, it has been suggested that an impaired signalling pathway via corticosteroid-activated mineralocorticoid and glucocorticoid receptors, leading to an impaired negative feedback regulation of the HPA system, causes this hyperactivity [21].”
BackgroundRaadsheer, F. C., Hoogendijk, W. J. G., Stam, F. C., Tilders, F. J. H., & Swaab, D. F. (2008) · Neuroendocrinology · doi:10.1159/000126778 · Cited by 667
The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders
Heuser, I., Yassouridis, A., & Holsboer, F. (1994) · Journal of Psychiatric Research · doi:10.1016/0022-3956(94)90017-5 · Cited by 662
The Dexamethasone Suppression Test for Diagnosis and Prognosis in Psychiatry: Commentary and Review
Arana, G. W. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790350067012 · Cited by 526
Purba, J. S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020055007 · Cited by 433 · cited 1×
“Findings in depressed patients of increased CRH levels in the CSF [17] and elevated numbers of CRH [18] and argininevasopressin (AVP) [19] expressing neurons in the paraventricular nucleus of the hypothalamus as well as the observation of reduced CRH binding sites in the frontal cortex of suicide victims [20] gave rea…”
BackgroundZobel, A. W., Nickel, T., Sonntag, A., Uhr, M., Holsboer, F., & Ising, M. (2001) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(01)00013-9 · Cited by 354
Ising, M., Horstmann, S., Kloiber, S., Lucae, S., Binder, E. B., Kern, N., Künzel, H. E., Pfennig, A., Uhr, M., & Holsboer, F. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.039 · Cited by 341 · cited 2×
“This is in line with studies reported by Ising and colleagues who found improved HPA system regulation in a second DEX/CRH test (performed 2 or 3 weeks after the first test at the beginning of the study) to be associated with beneficial treatment response after 5 weeks [51,54].”
MethodResultAdrenal Gland Enlargement in Major Depression: A Computed Tomographic Study
Nemeroff, C. B. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820050048008 · Cited by 283 · cited 1×
“In contrast to a reduced ACTH response to CRH, depressive patients show both an enlargement of the adrenal gland [11,12] and elevated COR stimulation patterns indicating an enhanced adrenal sensitivity after challenge with ACTH in most [13–15] but not all [16] studies.”
ResultPlasma cortisol in depressive illness
Gibbons, J. L., & McHugh, P. R. (1962) · Journal of Psychiatric Research · doi:10.1016/0022-3956(62)90006-7 · Cited by 256
Kunugi, H., Ida, I., Owashi, T., Kimura, M., Inoue, Y., Nakagawa, S., Yabana, T., Urushibara, T., Kanai, R., Aihara, M., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300868 · Cited by 200
Neuroendocrinological mechanisms of actions of antidepressant drugs
Schüle, C. (2007) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2006.01516.x · Cited by 167 · cited 1×
“Reuptake inhibiting antidepressants such as reboxetine, selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants acutely stimulate cortisol and ACTH secretion both in healthy subjects [69] and in depressed patients [70,71] after single administration and may gradually normalize HPA axis hyperactivi…”
BackgroundSelf-citationvon Bardeleben, U., & Holsboer, F. (1989) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.1989.tb00150.x · Cited by 161
Holsboer-Trachsler, E., Stohler, R., & Hatzinger, M. (1991) · Psychiatry Research · doi:10.1016/0165-1781(91)90041-m · Cited by 160 · cited 1×
“A gradual down-regulation of HPA axis hyperactivity in depressed patients as measured by serial DEX/CRH tests has been demonstrated for tricyclic antidepressants such as amitriptyline [26], doxepin [27], trimipramine [28–31], for the selective serotonin-reuptake inhibitor paroxetine [32], for tianeptine which enhances…”
MethodAppelhof, B. C., Huyser, J., Verweij, M., Brouwer, J. P., van Dyck, R., Fliers, E., Hoogendijk, W. J. G., Tijssen, J. G. P., Wiersinga, W. M., & Schene, A. H. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.008 · Cited by 154 · cited 1×
“. In addition, in outpatients with clinically remitted major depression, higher cortisol levels in the DEX/CRH test are apparently associated with relapse of major depression”
BackgroundClinical and Neurobiological Effects of Tianeptine and Paroxetine in Major Depression
Nickel, T., Sonntag, A., Schill, J., Zobel, A. W., Ackl, N., Brunnauer, A., Murck, H., Ising, M., Yassouridis, A., Steiger, A., et al. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200304000-00008 · Cited by 152 · cited 1×
“A gradual down-regulation of HPA axis hyperactivity in depressed patients as measured by serial DEX/CRH tests has been demonstrated for tricyclic antidepressants such as amitriptyline [26], doxepin [27], trimipramine [28–31], for the selective serotonin-reuptake inhibitor paroxetine [32], for tianeptine which enhances…”
MethodStout, S. C., Owens, M. J., & Nemeroff, C. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.1085 · Cited by 117 · cited 1×
“Reuptake inhibiting antidepressants such as reboxetine, selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants acutely stimulate cortisol and ACTH secretion both in healthy subjects [69] and in depressed patients [70,71] after single administration and may gradually normalize HPA axis hyperactivi…”
Background
Cited by
Binder, E. B. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.05.021 · Cited by 968
“This might have facilitated the normalization of HPA-axis hyperactivity that is associated with clinical response to most antidepressant treatments (see Ising et al., 2007; Binder et al., 2008; Horstmann et al., 2009; Hennings et al., 2009; Schule et al., 2009).”
BackgroundBiological and psychological markers of stress in humans: Focus on the Trier Social Stress Test
Allen, A. P., Kennedy, P. J., Cryan, J. F., Dinan, T. G., & Clarke, G. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.11.005 · Cited by 734
Frodl, T., & O'Keane, V. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.03.012 · Cited by 555
Stress Hormone Regulation: Biological Role and Translation into Therapy
Holsboer, F., & Ising, M. (2010) · Annual Review of Psychology · doi:10.1146/annurev.psych.093008.100321 · Cited by 473
“…depression, as normalization of subsequent test results predicts beneficial clinical outcome (Appelhof et al. 2006; Binder et al. 2009; Hatzinger et al. 2002; Hennings et al. 2009; Heuser et al. 1994; Holsboer-Trachsler et al. 1991; Ising et al. 2005, 2007a; Schüle et al. 2009; Zobel et al. 1999).”
BackgroundA users guide to HPA axis research
Spencer, R. L., & Deak, T. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.11.014 · Cited by 405
Metadata
- Authors
- Schüle, C., Baghai, T. C., Eser, D., Häfner, S., Born, C., Herrmann, S., & Rupprecht, R.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-01-30
- Volume
- 4
- Issue
- 1
- Pages
- e4324
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2021954132
- Cited by
- 83
- References
- 19
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.